Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of XL999 Administered Intravenously to Subjects With Recurrent Ovarian Cancer

NCT00277290 is registered in ClinicalTrials.gov with Symphony Evolution, Inc. as lead sponsor.

NCT NCT00277290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00277290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of XL999 Administered Intravenously to Subjects With Recurrent Ovarian Cancer
Lead sponsor
Symphony Evolution, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2006
Completion date
November 30, 2006
Enrollment
24 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer